Bicycle Therapeutics plc American Depositary Shares - BCYC STOCK NEWS

ResearchAndMarkets.com has released the report "Global Genetic Disorders Partnering 2016-2023," providing a comprehensive overview of genetic disorder deals signed worldwide since 2016. The report captures key aspects including deal trends, financial terms, and the most active dealmakers in the biopharma industry. It includes detailed analyses of deal structures, contract documents, and financial metrics, such as headline values, upfront payments, and royalty rates. Covering multiple genetic disorders like Cystic Fibrosis and Huntington's Disease, this report aims to be an essential resource for stakeholders in genetic disorder collaborations.

The report titled Global Cardiovascular Partnering 2016-2023, released by ResearchAndMarkets.com, analyzes cardiovascular disease deals from major pharmaceutical and biotechnology firms worldwide since 2016. Key insights include trends in cardiovascular partnering, financial deal terms, and structures.

It evaluates over 850 cardiovascular deals, detailing upfront payments, milestone payments, and royalties. The report is segmented to provide valuable benchmarking and analysis, including an overview of leading dealmakers and the financial metrics of significant agreements. This resource aims to inform prospective dealmakers in cardiovascular technology and product commercialization.

Bicycle Therapeutics (NASDAQ: BCYC) has appointed Santiago Arroyo, M.D., Ph.D., as Chief Development Officer effective March 31. Dr. Arroyo brings over 20 years of experience, having previously served as Chief Medical Officer at Momenta Pharmaceuticals. He will oversee the clinical development of Bicycle’s expanding pipeline, including programs in oncology. Jennifer Perry, Pharm.D., has been promoted to Senior Vice President, Commercial, with over 15 years of experience in oncology. The transition includes the departure of Chief Medical Officer Dr. Dominic Smethurst. These leadership changes aim to position Bicycle for continued growth and success in late-stage development.

Bicycle Therapeutics has announced a strategic collaboration with Novartis to develop targeted radioligand therapies for oncology. Under this agreement, Bicycle will receive a $50 million upfront payment and potential milestone payments totaling up to $1.7 billion. Novartis will manage the further development and commercialization of the BRCs, funding all associated costs. This partnership aims to leverage Bicycle's proprietary technology in the creation of precision-guided radiopharmaceuticals, enhancing its clinical development efforts in cancer treatment.

Bicycle Therapeutics (NASDAQ: BCYC) announced participation in two investor conferences in March 2023. The company will host a fireside chat at Cowen's 43rd Annual Health Care Conference on March 7 at 9:50 a.m. ET, and at the Barclays Global Healthcare Conference on March 16 at 9:00 a.m. ET. Live webcasts of these discussions will be available on the company's website, with archived replays accessible for 90 days post-event. Bicycle Therapeutics specializes in developing a new class of therapeutics using its proprietary Bicycle technology, targeting underserved diseases with high-affinity and selectivity.

Bicycle Therapeutics (NASDAQ: BCYC) reported fourth-quarter and full-year 2022 results, highlighting significant progress with advanced clinical trials for BT8009, BT5528, and BT7480. BT8009 received Fast Track Designation from the FDA, and Phase I results showed anti-tumor activity in treated patients. The company has a cash position of $339.2 million, expected to support operations into 2025. R&D expenses rose to $81.6 million in 2022, leading to a net loss of $112.7 million, or $(3.80) per share. Further updates on trials are anticipated by the end of 2023, positioning the company for future milestones.

Bicycle Therapeutics (NASDAQ: BCYC) announced promising results from the Phase I trial of BT8009, a novel BTC targeting Nectin-4, showing a 50% overall response rate and a 75% clinical benefit rate in urothelial cancer. A complete response was recorded at the 5 mg/m² dose. As of January 2023, the median duration of response is approximately 14 months for urothelial patients. The trial also confirmed responses in non-small cell lung cancer (NSCLC) and breast cancer patients. The company plans to advance to a Phase II trial and continue expansion cohorts.

Bicycle Therapeutics plc (NASDAQ:BCYC), a pioneering biotechnology firm, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 9:20 a.m. ET. This event will be held virtually, and a live webcast will be accessible on their website, www.bicycletherapeutics.com. The archived version of the chat will be available for 90 days. Bicycle Therapeutics specializes in developing novel therapeutics, called Bicycles, which are designed for diseases lacking effective treatments. Their ongoing clinical trials include BT5528, BT8009, BT7480, and BT1718, targeting various significant tumor antigens.

The report titled "Non-Viral / Intracellular Drug Delivery Systems Market" by ResearchAndMarkets.com highlights the rising demand for efficient drug delivery systems in the biopharmaceutical industry. It notes that over 20% of the proteome resides within cell membranes, necessitating innovative delivery methods for therapeutic intervention. Key advancements include non-viral systems such as exosome-based techniques and cell-penetrating peptides. The report reveals that around 1,300 patents have been filed, indicating substantial innovation, with over 20,000 studies on oligonucleotide-based therapeutics underway. The market is expected to grow significantly in the near term.